Trial Profile

PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering From Metastatic Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms PERSEUS-1

Most Recent Events

27 Jan 2024 Results of stage 1 (n=25) presented at the 2024 Genitourinary Cancers Symposium.
21 Dec 2018 Status changed from not yet recruiting to recruiting.
15 Nov 2018 Planned initiation date changed from 8 Oct 2018 to 30 Nov 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com